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ABSTRACT The HIV-1 integrase enzyme is responsible for one of the key stages of retroviral replication; it acts 
as a catalyst for the integration of viral cDNA into the cell’s genome. Inhibitors of HIV-1 integration have been 
under development for over 10 years; yet, only one integration inhibitor, raltegravir, has been approved for 
clinical use so far. Raltegravir binds two metal ions in the enzyme’s active centre and blocks one of the integra-
tion stages: the strand transfer. Unfortunately, the clinical use of raltegravir results in the development of viral 
resistance among some patients. Several more HIV-1 integration inhibitors are undergoing clinical trials at the 
moment. However, the structure and mechanism of action of those are similar to raltegravir, which results in the 
emergence of cross resistance with raltegravir. The present review is focused on the history of the development 
and clinical trials of raltegravir and its analogues, the problems connected with the emergence of viral resistance 
to integration inhibitors, and the prospect of their future clinical use.
KEYWORDS HIV-1 integrase; inhibition; mechanism of action; raltegravir.
ABBREVIATIONS HAART – highly active antiretroviral therapy; HIV-1 – human immunodeficiency virus type 1; 
IN – integrase; ST – strand transfer; AIDS – acquired immunodeficiency syndrome; AUC – area under the phar-
macokinetic curve (concentration–time curve) – the change in concentration of the active component in blood 
plasma or serum over time; СIC50 – the inhibitor concentration at which the cytopathogenic effect of the virus in 
the infected cells decreases by 50%; CIC95 – the inhibitor concentration at which the cytopathogenic effect of the 
virus in the infected cells decreases by 95%; Сlp – clearance, or the extraction ratio – the index showing the rate 
of extraction of a substance from blood plasma during the biotransformation of this substance, its redistribution 
in the organism, and excretion; Cmax – the maximum or peak of concentration of an active component in blood; 
EC50 – inhibitor concentration, at which in vivo replication of the virus is suppressed by 50%; EC90 – inhibitor 
concentration, at which in vivo replication of the virus is suppressed by 90%; F – bioavailability – the fraction of 
a dose of unchanged drug administered orally that reaches the systemic circulation; FBS – fetal bovine serum; 
FDA –  Federal Drug Administration (United States); IC50 – inhibitor concentration, at which the enzyme activ-
ity is suppressed by 50%; NHS – normal human serum; PPB – percentage plasma protein binding; Т1/2 – time by 
which the concentration of a drug in plasma decreases twice; WT – wild type.
INTRODUCTION
The acquired immunodeficiency syndrome (AIDS) be-
gan as  one of the most dramatic epidemics of the late 
20th – early 21st centuries. AIDS is caused by the hu-
man immunodeficiency virus (HIV) afflicting the im-
mune system of the organism. Ukraine and Russia have 
some  of the highest  rates of the spread of the HIV in-
fection in the world. HIV prevalence among the adult 
population in Russia is over 1.1% [1], according to some 
estimates. This is precisely why the development of ef-
fective therapeutic drugs to control the spread of the 
virus is particularly urgent for Russia.
HIV afflicts primarily the cells of the immune sys-
tem: the CD4+ Т-lymphocytes, macrophages, and 
dendritic cells. The stock of CD4 + cells is gradually 
depleted, resulting in the subsiding of  cell immunity. 
When a critical lymphocyte level is achieved, the or-
ganism becomes easy prey for  opportunistic infections 
[2]. The following stages of the HIV-infection  can be 
distinguished in the absence of antiretroviral therapy: 
the primary infection – acute HIV syndrome that ends 
with the extinction of clinical symptoms and serocon-
version; the latent stage (symptom-free chronic HIV 
infection); symptomatic HIV infection (AIDS), which is 
often accompanied by the development of opportunis-
tic infections; and the terminal stage (death) [2].
The replication cycle of HIV-1 can be tentatively 
divided into two phases: the early phase and the late 
phase (Fig. 1) [2, 3]. At the early stage of the life cycle, 
viral particles specifically bind onto the CD4 surface REVIEWS
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protein thanks to the specific interaction between the 
viral coat glycoprotein gp120 and the N-terminal do-
main of the immunoglobulin of the CD4 protein. The 
binding onto the CD4 receptor allows gp120 to bind to 
the coreceptors (CCR5 or CXCR4) on the surface of a 
target cell, as well. After the binding of g120 to core-
ceptors, glycoprotein gp41 is incorporated into the cell 
membrane, resulting in the fusion of the viral coat and 
the cell membrane yielding a pore, through which the 
viral core penetrates into the cell cytoplasm [2]. After 
the fusion, the virus sheds its coat, and the process of 
reverse transcription begins. The reverse transcription 
of genomic RNA is carried out via the viral enzyme; 
reverse transcriptase, in cytoplasm. The product of re-
verse transcription, double-stranded cDNA, is trans-
ported into the nucleus within the pre-integration 
complex, which comprises a number of viral proteins, 
such as integrase (IN), the matrix protein (MA), reverse 
transcriptase, the nucleocapsid protein (NC), and the 
regulatory protein Vpr (Viral Protein R) [4, 5], as well 
as the cell proteins Ku [6], HMG I(Y) [7], BAF [8], and 
LEDGF/p75 [9]. The nuclear localization of IN, MA, Vpr 
[5], and LEDGF/p75 [9] is ensured by nuclear localiza-
tion signals. After it is transported into the nucleus, a 
DNA copy is integrated, i.e., covalently incorporated 
into the genome of the host cell due to the catalytic ac-
tivity of IN [3]. The late phase of the replication cycle of 
HIV-1 begins with the regulated expression of the pro-
viral genome; then, processing of the synthesized viral 
proteins with viral protease occurs, followed by the as-
sembly of new virions, which are released from the cell 
and infect new target cells, ultimately terminating the 
life cycle of the virus [2, 3].
Highly active antiretroviral therapy (HAART), which 
at the time of writing comprises 25 drugs, is used in the 
treatment of HIV infection [10]. These drugs mostly in-
clude nucleoside and non-nucleoside inhibitors of re-
verse transcriptase of HIV-1 and protease inhibitors. 
Moreover, entry inhibitors have recently been designed: 
maraviroc, which blocks the interaction between gp120 
and CCR5, and enfuvirtide, which interacts with gp41 
glycoprotein (Fig. 1). At the end of 2007, the U.S. Food 
and Drug Administration (FDA) approved the first inte-
gration inhibitor, IsentressTM drug, also known as ralte-
gravir (MK-0518), an anti-AIDS agent [11].
The stage at which the viral DNA is integrated into 
cell DNA is one of the key stages in the replication cy-
cle of HIV-1; therefore, IN catalyzing is considered to 
be one of the most attractive targets for HIV-1 inhibi-
tors. It has been demonstrated that а virus containing 
a defective IN, which is incapable of catalyzing the in-
tegration of  viral DNA, cannot be reproduced in cell 
culture [12]. Moreover, IN does not have a cell equiva-
lent; therefore, the inhibitors that specifically suppress 
its catalytic activity are supposed to have no effect on 
the cell processes and should be less toxic for the cell 
and the entire organism in comparison to the inhibi-
tors of other stages of the HIV replication cycle. Over 
many years, the development of integration inhibitors 
has been pursued, with various drugs capable of block-
ing IN  described in minute detail in numerous reviews 
[13–19]. The present review is devoted to  state-of-the-
art studies in the field of  application of raltegravir and 
its analogues as HAART components.
INTEGRASE STRUCTURE AND INTEGRATION MECHANISM
The integration process begins in cytoplasm and com-
prises several stages [20–22]. A DNA copy of the viral 
RNA contains long terminal repeats at both ends, which 
consist of three fragments: U3, R, and U5. At a distance 
of two nucleotides from the 3’ terminus of each DNA 
strand, there is a conservative CA dinucleotide, which 
is found in the long terminal repeats of all retroviruses. 
Within the preintegration complex, IN recognizes the 
nucleotide sequences located at the termini of regions 
U3 and U5 of the viral cDNA, binds to them, and cata-
lyzes the reaction of 3’-terminal processing. This reac-
tion represents the endonuclease cleavage of the viral 
cDNA, resulting in the removal of the GT dinucleotide 
from the 3’ terminus in each strand. Substrate cleavage 
is caused by the nucleophilic attack on the phosphate 
group between the second and third nucleotides by a 
water molecule [20–22].
Entry inhibitors
Binding to the  
CD4 receptor
Fusion
Reverse 
transcriptase 
inhibitors
Integrase 
inhibitors
Release
Protease  
inhibitors
New  
virus
Binding
Viral protein
Transcription
Viral  
RNA
Provirus
Integration with 
DNA of the host
Double-
stranded 
DNA
Virion  
RNA
Reverse transcriptase
DNA synthesis 
on virion RNA
Fig. 1. HIV-1 replication cycle and HAART targets.14 | ACTA NATURAE |  VOL. 3  № 3 (10)  2011
REVIEWS
The pre-integration complex is then transported into 
the nucleus, where IN catalyzes the strand transfer 
(ST) stage. This stage is represented by the re-esterifi-
cation reaction, which involves the nucleophilic attack 
on the internucleotide phosphates of both strands of 
cellular DNA (DNA targets) by 3’-hydroxylic groups of 
the processed strands of viral (substrate) DNA, yield- , yield-  yield-
ing a covalent product. The internucleotide bonds lo-
cated in different strands of the DNA target at a dis-
tance of 5 np from each other undergo re-esterification. 
The completion of integration requires the following 
processes: processing of the 5’-termini of viral DNA, 
polymerase addition of five lacking nucleotides, and li-
gation, which are performed with the participation of 
cell proteins [20].
In the integration process, IN is required to bind two 
termini of the viral DNA to the cell DNA. However, 
the data on the interaction between IN and DNA as 
yet remains quite limited. HIV-1 integrase is a protein 
consisting of 288 amino acid residues (32 kDa) encoded 
by the pol viral gene. IN is translated within the Gag-
Pol polypeptide, which is subsequently cleaved into 
separate proteins by a viral protease [21]. It has been 
demonstrated by partial proteolysis and targeted mu-
tagenesis that three domains can be isolated in the en-
zyme structure: the N-terminal domain, comprising the 
amino acid residues 1–50; the catalytic domain formed 
by residues 51–212; and the C-terminal formed by the 
amino acid residues 213–288 (Fig. 2) [20].
The N-terminal domain contains two histidine and 
two cysteine residues, which are conservative in ret-
roviral integrases and retrotransportases [20]. These 
residues coordinate the zinc ion and participate in the 
formation of a catalytically active IN multimer, since 
it has been demonstrated that the coordination of Zn2+ 
ions stimulates IN multimerization and its activity [23]. 
The catalytic domain of IN contains the triad of invari-
ant amino acid residues (D64, D116, and E152 in HIV-1) 
which form the active centre of retroviral integrases. 
The catalytic domain participates in the binding of the 
termini of viral DNA due to their interaction with con-
servative amino acid residues of the domain (prima-
rily Q148, K156 and K159). For the integration to be 
possible, IN demands the presence of ions of cofactor 
metal ions (Mg2+ or Mn2+), which are coordinated with 
two residues from the catalytic triad (D64 and D116) 
[21]. The least conservative C-terminal domain forms 
the Src homology 3-like fold; this structural motif is 
N-terminal   Catalytic   C-terminal
1   50   212   288
H    H       C   C   D            D        E
12  16      40   43    64        112     152
  binding to Zn2+  chelating with Mg2+    nonspecific
  multimerization  catalysis and DNA binding  DNA binding
Fig. 2. Structural 
domains of HIV-1 
integrase [14].REVIEWS
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involved in IN multimerization; however, it makes the 
greatest contribution to the formation and stabiliza-
tion of DNA complexes that are either specific to the 
sequence or nonspecific. A non-typical double signal of 
nuclear localization located in the catalytic (186KRK188) 
and C-terminal (211KELQKQITK219) IN domains is rec-
ognized by the participants of the importine/caryo-
pherine cellular path. This interaction is enough to 
involve the PIC into the cell nuclear transport system 
[24].
The structure of full-scale HIV-1 IN remain un-
known; only the structure of separate domains and 
double-domain IN fragments has been determined (see 
[20]). These data, along with the results obtained using 
site-directed mutagenesis and cross-linking, have been 
used to design computer models of IN [25–27]. Regard-
less of the fact that these models often contradict each 
other, most researchers share the opinion that the te-
trameric form of IN is the one that functions in the cell. 
This viewpoint was confirmed by Hare et al. [28], who 
were the first to succeed in crystallizing and decoding 
the structure of retroviral IN in a complex with DNA. 
The IN of the human foamy virus belonging to the ret-
roviruses from the Spumaviridae subgroup, which was 
used with this purpose in mind, is active in tetrameric 
form. A tetramer consists of asymmetrical dimers, each 
of those interacts with one terminus of viral DNA and 
performs its integration into cellular DNA [28]. The 
comparative study of the catalytic characteristics of 
the IN of the human foamy virus and HIV-1 revealed a 
considerable similarity in the functioning of these two 
enzymes [29, 30].
Both the cellular and viral proteins that are com-
ponents of the preintegration complex can  affect  the 
catalytic activity of IN. HIV-1 IN needs neither viral 
nor cellular cofactors for the incorporation of both 
ends of the viral DNA into the super-spiralized cel -
lular DNA [31]. However, it has been demonstrated 
that such proteins as the NC viral protein and cellu-
lar proteins HMG I(Y) and LEDGF/p75 can enhance 
the integration efficiency [21, 32]. It has been known 
that cellular protein LEDGF/p75 immediately inter-
acts with IN and stimulates consistent integration and 
IN strand transfer [33]. It is assumed that LEDGF/p75 
can play the role of the chaperone with respect to IN, 
stabilizing its multimeric organization, and enhancing 
the IN affinity towards DNA [21].
DESIGNING HIV-1 INTEGRATION INHIBITORS 
SUPPRESSING THE STRAND TRANSFER REACTION
Since there has been no data available pertaining to the 
structure of HIV-1 IN, screening of libraries of chemi-
cal compounds of various classes has for a considerable 
period remained the primary method in the search 
for its inhibitors [4]. Testing of a library consisting of 
250,000 compounds that  ended by the year 2000 al-
lowed  specialists at Merck Pharmaceuticals  (United 
States) to reveal a series of substances possessing the 
highest IN-inhibiting activity among them [34]. It ap-
peared that all these substances are diketo compounds 
(DKC); notably, derivatives of 2,4-dioxobutanic acid. 
The inhibitors contained the so-called β-diketo acid 
motif, capable of coordinating cofactor metal ions in the 
IN active center [34]. These inhibitors manifested high-
er activity when inhibiting the strand transfer reaction 
than upon in vitro inhibition of the 3’ processing. The 
most active compound, L-731.988 (Fig. 3), was more ac-
tive by a factor of 70 with respect to the strand transfer 
reaction in comparison with the 3’ processing reaction. 
Moreover, this inhibitor suppressed the development of 
HIV-1 in a cell culture (Table 1).
The selection of virus strains stable towards the ac-
tion of DKC was performed, followed by the determi-
nation of the mutation site.  Replacement of the М154 
(M154I) residue located in the immediate proximity of 
the E152 residue (a component of the catalytic triad of 
the enzyme) was found to exist in the IN of a strain  re-
sistant to the action of L-731.988 [34].
The interaction between L-731.988 and IN has been 
subsequently studied [38]. It has been demonstrated 
that the inhibitor, at concentrations up to micromo-
lar ones, does not interact with the isolated enzyme. 
A DNA substrate, U5 or U3-terminal fragments of 
the viral DNA are required for its binding with the 
enzyme. The dissociation constant (Kd) of the inte-
grase–L-731.988 complex determined in the presence 
of 100 nM of U5 substrate was equal to 75 nM, which 
correlated with the IC50 value in the strand transfer re-
action. The affinity of L-731.988 upon interaction with 
IN bound to the processed viral DNA was higher by a 
factor of 100 in comparison with that upon the interac-
tion with IN, in the absence of viral DNA (Kd = 10–20 
µM). The random sequence DNA did not stimulate in-
teraction between the inhibitor and the enzyme. Fur-
Table 1. Results of in vitro and cell studies of diketo acid 
L-731.988 and naphthyridine derivatives L-870.810 and 
L-870.812 as HIV-1 integration inhibitors
Integrase 
inhibitor
IC50 , in vitro
(strand transfer), 
nM
CIC95
ex vivo
L-731.988 8–15 [34] CIC50 = 1 µM [34]
L-870.810 8–15 [35] 15 nM (10% FBS)
100 nM (50% NHS) [36]
L-870.812 40 [36] 250 nM (50% NHS) [37]16 | ACTA NATURAE |  VOL. 3  № 3 (10)  2011
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thermore, an increase in the concentration of the DNA 
substrate, its excess amount being capable of acting as 
a DNA target, resulted in a decrease in inhibitor–IN 
binding. An assumption was made, based on these data, 
[38] that the L-731.988 inhibitor suppresses the strand 
transfer reaction by competing with a DNA target for 
its binding site; the conformation of the active enzyme–
substrate complex is required for the interaction be-
tween the inhibitor and IN.
A number of other substances have a similar nature 
of inhibition of the IN activity; their common feature 
being the presence of two oxygen atoms capable of co-
ordinating cofactor metal ions in the IN active center 
[39–42].
The search for DKS analogues demonstrating anti-
integrase activity resulted in the design of\ naphthyri-
dine derivatives by Merck Pharmaceuticals. The activ-
ity and selectivity of these compounds with respect to 
the strand transfer reaction was similar to that of DKC 
[43]. Among the inhibitors of this structural class, two 
inhibitors, L-870.810 and L-870.812, have been subject-
ed to the most thorough study (Fig. 2, Table 1).
A naphthyridine derivative L-870.810 displaced 
diketo acid L-731.988 from the IN/DNA-substrate 
complex, which enabled one to assume the possibil-
ity of binding of these compounds to IN at a single or 
overlapping site [36]. The accumulation of circular viral 
DNA in the treated L-870.810 cells and a decrease in 
the amount of integrated viral DNA served as  evidence 
of the action of this inhibitor on the integration process. 
The selection of virus strains that could be resistant to-
wards the action of L-870.810 resulted in the following 
substitutions in the primary structure of IN: F121Y/
T125K, V72I/F121Y/T125K, and V72I/F121Y/T125K/
V151I [36]. The viruses carrying the corresponding mu-
tations were less sensitive to the action of L-870.810 by 
a factor of 4–100 in comparison with wild-type HIV-1 
[36]. Mutations in the IN gene causing viral resistance 
to diketo acids and naphthyridines are closely located, 
but not identical. All these facts attest to the possibility 
of the existence of both a common binding centre and 
a common mechanism of action in inhibitors belonging 
to both classes.
Inhibitor L-870.810 successfully passed the first 
phase of clinical trials; however, at the second phase it 
proved toxic to kidneys and the liver. For this reason, 
the trials were ended.
RALTEGRAVIR (MK-0518) – THE FIRST INHIBITOR 
OF HIV-1 INTEGRATION ALLOWED FOR USE
Designing raltegravir 
The relative success achieved from the use of naphthy-
ridine derivatives as IN inhibitors led to the design of   
inhibitors based on dihydroxypyrimidine (compound 
(1), Fig. 4) [45]. This compound specifically suppress-
es the strand transfer carried out by recombinant IN 
(Table 2); however, even micromolar concentrations of 
this compound are inactive in the culture of infected 
cells. Nevertheless, due to its pharmacokinetic indices 
determined in rats (good bioavailability (F = 39%) and 
the low clearance of blood plasma (Clp = 11 mg/min/
kg)), this compound was selected for further structural 
and functional studies [45], enabling the design of this 
compound (2) (Fig. 4) [46]. The compound successfully 
inhibits the strand transfer reaction (Table 2) and sup-
presses the cytopic effect of HIV-1 in infected cells 
[46].
 Parallel studies resulted in the design of a novel 
class of IN inhibitors, N-alkyl pyrimidinone derivatives, 
which inhibited the nanomolar concentrations of IN in   
in vitro experiments [36]. The results of the study of 
the inhibiting effect of compound (3) (Fig. 4), belong-
ing to this class, are listed in  Table 2 [47]. Moreover, 
compounds (2) and (3) were characterized by a strong 
pharmacokinetic profile and strong bioavailability in 
preclinical trials performed on rats, dogs, and rhesus 
macaques [46, 47].
An attempt was then made to combine the optimal 
properties of inhibitors from each of the two series in 
one molecule [48]. This approach resulted in the design 
of another N-methyl pyrimidinone derivative (com-
pound (4), Fig. 4). However, compound (4) turned out 
to be less active (Table 2).
The structural and functional studies of N-methyl 
pyrimidinone derivatives as IN inhibitors were contin-
ued [48]. Compound MK-0518 (Table 2), which was giv-
en the name ‘Raltegravir’ (Fig. 4), appeared to be the 
L-731.988
L-870.810 L-870.812
Fig. 3. Structure of HIV-1 integration inhibitors: 
L-731,988, L-870,810, and L-870,812.REVIEWS
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most active. It turned out that raltegravir has a high se-
lectivity with respect to IN and has almost no inhibiting 
effect (IC50 > 50 µM) on such Mg2+-depending enzymes 
as HIV-1 reverse transcriptase, HIV-1 RNAse H, hepa-
titis C virus RNA polymerase, and human polymerases 
α, β, and γ [48]. No effect of raltegravir (at concentra-
tions of up to 10 µM) on another 150 different enzymes, 
receptors, and channels has been revealed. In partic-
ular, raltegravir has no effect on various cytochrome 
P450 isoforms (IC50 > 50 µM) and does not bind to the 
hERG ion channel [48].
Pharmacokinetics and interaction 
with HAART components
The pharmacokinetic profile of raltegravir has been 
studied on rats, dogs, and rhesus macaques [48]. The 
rats were given raltegravir in three different forms 
(OH form, as well as Na+ and К+ salts) at a dose of 3 mg/
kg. The best results were achieved when using ralte-
gravir salts. The amount of the compound that entered 
the blood upon one-time administration (AUC) was the 
highest for Na+ salt; the maximum peak of compound 
concentration in blood (Сmax) was attained in K+ salt. In 
this case, values AUC and Сmax were also better in the 
salt form of the preparation (Table 3). The dogs were 
given raltegravir in the form of the OH form or K + 
salt at a dose of 10 mg/kg. In this case, AUC and Сmax 
values were also better for the salt form of the drug 
(Table 3). The crystalline OH form at a dose of 10 mg/
kg was also administered to rhesus macaques, but the 
AUC and Сmax indices were quite low (Table 3). The bio-
availability of the drug administered orally (F) also ap-
peared to be better for the K+ salt in comparison with 
that for the OH form (Table 3). Hence, the pharmacoki-
netic profile of raltegravir in the form of Na + and К+ 
salts was found to be preferable to that of the OH form; 
salt forms being characterized by improved solubility 
[48].
Blood plasma clearance was appreciably low in dogs 
and was characterized by medium values in rats and 
rhesus macaques (Table 3). Furthermore, raltegravir 
binding to the blood plasma proteins (PPB) of rats, 
dogs, and rhesus macaques has been the subject of a 
study (Table 3) [48], as well as its metabolism in the 
liver microsomes of these animals and humans. It ap-
peared that the drug is metabolized by glucuronosyl-
transferase [48]. The same conclusion was made after 
studying the metabolism in hepatocytes [48] and was 
borne out by the results of an independent study [49]. 
1Н- and 13С-NMR spectroscopy was used to completely 
characterize the formation of a conjugate between glu-
Table 2. Results of in vitro and cell studies of derivatives 
of dihydroxypyrimidine and N-methylpyrimidinone and 
raltegravir (MK-0518) as HIV-1 integration inhibitors
Compound
IC50 ,in vitro
(strand 
transfer), nM
CIC95
ex vivo Reference
(1) 10 inactive [45]
(2) 50 60 nM (10% FBS)
78 nM (50% NHS) [46]
(3) 60 60 nM (10% FBS)
100 nM (50% NHS) [47]
(4) 250 1 µM (10% FBS)
> 1 µM (50% NHS) [48]
MK-0518 15 19 nM (10% FBS)
31 nM (50% NHS) [48]
(2)
(1) (4)
(3)
MK-0518
Fig. 4. Optimiza-
tion of dihydrox-
ypyrimidine (1, 
2) and N-methyl 
pyrimidinone 
carboxamides 
(3, 4) as HIV-1 
integrase strand 
transfer inhibi-
tors, which led 
to the design 
of raltegravir 
(inhibitor MK-
0518).18 | ACTA NATURAE |  VOL. 3  № 3 (10)  2011
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curonide and a hydroxylic group at position 5 of the py-
rimidinone ring of raltegravir [48].
The comparison of in vivo and in vitro data allowed 
one to suppose [48] that the pharmacokinetic profile 
of raltegravir for humans will be similar to the drug 
profile for a dog.
To achieve a therapeutic effect, it is necessary that 
the drug concentration 12 h after the administration 
(С12) remain above CIC95 = 31 nM. With account for the 
data on raltegravir binding with blood plasma proteins, 
metabolic stability, half-excretion period, and clear-
ance, peroral administration of raltegravir К+ salt at a 
dose of at least 100 mg twice a day was proposed during 
the clinical trials.
The pharmacokinetic profile of raltegravir was de-
termined both in healthy volunteers and HIV-infected 
patients. Two randomized placebo-controlled trials 
were carried out with healthy volunteers: 32 volunteers 
were given a single dose of raltegravir (10–1600 mg); 
and raltegravir was administered to 40 volunteers eve-
ry 12 h for a duration of 10 days (100–800 mg) [50]. It 
was ascertained that raltegravir is characterized by a 
good assimilability; its content in blood plasma attain-
ing the maximum level (Сmax) as early as after 1 h. The 
half-excretion period of the drug (Т1/2) was equal to 
7–12 h. The drug concentration in the blood becomes 
constant as early as 2 days after its administration; 
after the administration is stopped, only weak accu-
mulation in the organism is observed [50]. Moreover, it 
should be noted that no considerable differences were 
revealed to administration of the drug in the male or 
female volunteers.
The pharmacokinetics of raltegravir was also stud-
ied among HIV-infected antiretroviral treatment-naïve 
patients [51]. It was ascertained that the AUC and Сmax 
values increase in geometrical progression up to the ad-
ministration of raltegravir, at a dose of 400 mg, twice a 
day. At a dose of 600 mg, these parameters do not in-
crease [51]. Moreover, an approximately threefold de-
crease in the viral load in HIV-infected patients was 
observed, regardless of the dose of the administered 
drug [51]. Nevertheless, the latter results should be 
taken  with great care due to the relatively small size of 
the sampling and short duration of the study.
The interaction of raltegravir with various compo-
nents of HAART antiviral therapy in healthy volun-
teers has also been studied (see [52]). It appeared that 
the simultaneous administration of raltegravir and pro-
tease inhibitors – atazanavir and atazanavir/ritonavir 
mixture – increases raltegravir concentration in the 
blood to a certain extent, whereas ritonavir alone has 
almost no effect on the raltegravir concentration. The 
nucleotide inhibitor of reverse transcriptase, tenofir, 
also had a negligible effect on the raltegravir concen-
tration. The administration of raltegravir, together 
with tipnavir (protease inhibitor), maraviroc (penetra-
tion inhibitor), efavirenz, and etravirine (both drugs 
are non-nucleoside inhibitors of reverse transcriptase), 
resulted in a decrease in the raltegravir concentration 
in healthy volunteers.
Only one study of raltegravir interaction with 
HAART components has been carried out on HIV-in-
fected patients [53]. Four individuals were given ralte-
gravir (400 mg) twice a day, together with etravirine 
(non-nucleoside inhibitor of reverse transcriptase); the 
raltegravir concentration in the blood decreased by 
a factor of 4. Regardless of these results, the authors 
provide no recommendations on changing the dose of 
raltegravir when administering it together with etra-
virine [53]. Thus, the necessity for further study of the 
interaction between raltegravir with HAART compo-
nents in HIV-infected individuals becomes evident. 
Clinical trials
Treatment upon resistance to HAART. Firstly, the study 
of raltegravir in HIV-infected individuals who had re-
ceived HAART and acquired resistance to its compo-
nents was initiated. The randomized double-blind, 
placebo-controlled trial (P005) was carried out during 
24 weeks in research centres  within the United States, 
Europe, Latin America, and Asia [54]. The participants 
included adult patients (18 years and older) with a vi-
ral load of at least 5,000 HIV RNA copies/ml and with a 
level of CD+ lymphocytes of at least 50 cells/µl. The pa-
tients had also been receiving HAART on a regular ba-
sis for at least 3 months, and had  laboratory-confirmed 
genotypic or phenotypic resistance to at least one of the 
Table 3. Pharmacokinetic parameters of raltegravir determined for rats/dogs/rhesus macaques [48]
Form AUC, µM·h Cmax, µM T1/2, h F, % Clp, ml/min/kg PPB, %
OH 1.0/21/1.8 1.2/8/0.3 ND*/ND/7 37/45/8 39/6/18 74/71/85
Na+ 1.4/ND/ND 1.0/ND/ND ND/ND/ND ND/ND/ND ND ND
K+ 1.3/45/ND 1.6/24/ND 73/13/ND 45/69/ND ND ND
* ND – no data available.REVIEWS
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non-nucleoside inhibitors of reverse transcriptase, one 
nucleoside inhibitor of reverse transcriptase, and one 
protease inhibitor. Prior to the random grouping, the ba-
sic regimen of HAART was optimized for each patient; 
the amount of drugs administered varying from two to 
seven. It should be noted that the selection of antiretro-
viral agents for these patients was very limited due to 
the intolerance or HIV-1 resistance to them. Since it had 
been demonstrated earlier that the simultaneous admin-
istration of atazanavir (protease inhibitor) and raltegra-
vir may result in an increase in raltegravir concentra-
tion in the blood [50], the patients were divided into two 
subgroups, those with atazanavir  included within their 
basic regimen, and those without it [54].
The trial comprised 175 patients. All patients were di-
vided into groups, which were either given varying dos-
es of raltegravir or a placebo (Table 4). The clinical and 
demographic characteristics were similar for the groups. 
All patients underwent a 24-week therapy course. Ralte-
gravir as a supplement to the optimized HAART regi-
men showed  better efficacy in comparison with the pla-
cebo, at any given dose. A mean decrease in the viral load 
by 100 copies/ml was observed in all groups who were 
given raltegravir; it began as early as week 2 and was 
consistent up to week 24 (Table 4). The decrease in the 
viral load was accompanied by an increase in the CD4+ 
cell count (Table 4). Joint use of raltegravir and enfuvir-
tid (entry inhibitor) or atazanavir within HAART par-
ticularly improved the virological and immune response. 
Forty-one patients left the trial because of inefficacy, 14 
(11%) of the 144 who were given raltegravir and 27 (60%) 
of the 45 who received a placebo. It was demonstrated 
that raltegravir is a very safe drug: most of the side ef-
fects were of light or medium degree of severity. Only 
two patients left the trial as a result of the side effects 
of HAART (one in the raltegravir group, and one in the 
placebo group) [5 4].
The results of the P005 trial [54] in general are con-
sistent with the results of the long-term trial BENCH-
MRK-1 and -2 [55] devoted to the study of the efficacy 
and safety of using raltegravir in patients who had ear-
lier received HAART. After a 96-week study, it was 
found that the viral load had decreased and the CD4 
cell count had increased quite considerably in patients 
who were given raltegravir than it had in those who re-
ceived a placebo (Table 4). It should be mentioned that 
the optimum results were achieved when raltegravir 
was used in combination with darunavir (protease in-
hibitor) and enfuvirtid; the patients were naive to these 
drugs [55].
Primary therapy. Since raltegravir demonstrated 
positive results in patients who had earlier received 
HAART, it became attractive as a primary drug for 
HIV-infected patients naïve to HAART. The effect of 
raltegravir and efavirenz (non-nucleoside inhibitor of 
Table 4. Results of clinical trials of raltegravir
Name and duration  
of the trial Therapeutic strategy
Fraction of patients with an 
undeterminable viral load 
(< 50 copies/ml)
CD4 cell count, 
cells/µl Reference
Therapy upon HAART-resistance
P005, 24 weeks
200 mg ral.*, 41 h 65 63
[54]
400 mg ral., 44 h 56 113
600 mg ral., 45 h 67 94
Placebo, 45 hhh 13 5
BENCHMRK-1 and -2, 
96 weeks
400 mg ral., 462 h 58 123
[55]
Placebo, 237 hhh 26 49
Primary therapy
P004, 4 weeks
100 mg ral., 41 h 85 221
[56]
200 mg ral., 40 h 83 146
400 mg ral., 41 h 88 144
600 mg ral., 40 h 88 187
600 mg efv.*, 39 h 87 170
STARTMRK-1 and -2, 
48 weeks
400 mg ral., 281 h 86 189
[57]
600 mg efv., 282 h 82 163
Supporting therapy
CHEER, 24 weeks 400 mg ral., 52 h 94 32 [58]
* ral. – raltegravir.
** efv. – efavirenz.20 | ACTA NATURAE |  VOL. 3  № 3 (10)  2011
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reverse transcriptase) were compared in two series of 
clinical trials (P004 [56] and STАRTMRK-1 and -2 [57]). 
As a supplement to these drugs, the participants were 
given tenofovir and lamivudin (both drugs are nucle-
oside inhibitors of reverse protease) (P004 [56]) or teno-
fovir only (STARTMRK-1 and -2 [57]). It turned out 
that raltegravir was no less capable of reducing the vi-
ral load to below 50 copies/ml in comparison with efa-
virenz; the CD4 cell count being comparable for both 
drugs (Table 4). In addition, the therapeutic effect of 
raltegravir was observed earlier than that of efavirenz 
[57]. Although the reasons for such an effect have as 
yet remained unclear, this property of raltegravir can 
be potentially used when there is a necessity for a rapid 
decrease in the viral load after the HIV-infection, or to 
reduce the risk of transplacental infection of the foetus 
from a HIV-infected mother. It should also be noted 
that in general the results demonstrated in trials P004 
and STАRTMRK-1 and -2 were better than those in 
trials Р005 and BENCHMRK-1 and -2 (Table 4). This 
result posits the early commencement of raltegravir 
administration to HIV-infected patients. 
Supporting therapy. In addition to using raltegravir as 
a therapeutic agent in HAART-naive patients, as well 
as in patients who had developed resistance to HAART 
components, it was proposed to substitute antiretrovi-
ral drugs with raltegravir in patients with a viral load 
that cannot be determined, in order to reduce the side 
effects. Trial СHEER [58] included 52 patients with a 
viral load of less than 50 copies/ml, who were earlier 
given enfuvertid (penetration inhibitor). Twenty-four 
weeks after transferring to raltegravir, the undeter-
minable viral load remained in 49 patients (Table 4). 
Based on these results, a conclusion can be drawn that 
the substitution of enfuvertid by raltegravir seems to 
be appreciably safe.
Safety
How safe Raltegravir is  was evaluated both in HIV-
infected patients naïve to HAART and in patients who 
developed resistance to HAART components. All stud-
ies demonstrated a strong degree of drug tolerance 
[51, 56, 57]. Raltegravir turned out to be safer than 
efavirenz upon primary therapy of HIV-infected pa-
tients [57]. How safe  raltegravir is was assessed on 
patients who had earlier received HAART. Recur -
rent or progressing cancer types were detected in ap-
proximately 3.5% of patients who were administered 
raltegravir, whereas this index was equal to 1.7% in 
individuals taking a placebo. Such types of cancers   
as Kaposi’s sarcoma, lymphoma, hepatic cancer, etc. 
were the most common [54]. The thorough analysis of 
all cases of cancer development in patients who were 
administered raltegravir revealed no correlation be-
tween drug administration and the emergence of ma-
lignant tumors [52].
Usage guidelines
Raltegravir successfully passed all phases of clinical 
trials in October 2007 and was approved by the FDA 
as a therapeutic agent for patients with resistance to 
HAART components [1]. In July 2009, the FDA also au-
thorized the use of raltegravir for  primary therapy of 
HIV-infected patients [59]. Raltegravir was registered 
under the trademark IsentressTM; it is manufactured in 
the form of 400 mg tablets for twice-daily oral admin-
istration.
Development of resistance to raltegravir
Raltegravir has been used with appreciable suc -
cess as one of the components of HAART; however, a 
number of patients developed resistance to this drug 
[60]. It was ascertained during the trial BENCHMRK-1 
and -2 that 48 weeks after raltegravir administration 
commenced, resistance to this drug was developed in 
approximately 25% of patients. Virus isolates were ob-
tained from 94 patients with resistance. No mutations 
in the IN genes were found in 30 isolates; whereas in 
the remaining 64, the development of resistance was 
accounted for by these mutations [60]. The resistance to 
strand transfer reaction is usually associated with the 
mutations in the IN active center [61]. It was in the ac-
tive center that raltegravir-resistant virus isolates con-
tained the primary mutations Y143R/C, Q148K/R/H, 
and N155H [60]. In most patients (48 out of 64), the vi-
rus had at least two mutations. Typically, it was a pri-
mary mutation and one or several secondary mutations. 
The primary mutation Y143R/C was associated with 
the secondary mutations L74A/I, E92Q, T97A, I203M 
and S230R; the mutation Q148K/R/H was associated 
with mutations G140S/A and E138K. Primary muta-
tion N155H was associated with a number of secondary 
mutations: L74M, E92Q, T97A, V151I, and G163R [60]. 
In addition, it was ascertained that it is typical for mu-
tations to accumulate with time. At the first instance, 
it refers to the Q148R substitution, which renders the 
virus almost unsusceptible to raltegravir. The fraction 
of carriers of the virus containing this mutation among 
raltegravir-resistant patients after undergoing therapy 
for 48 weeks was equal to 27%; after 96 weeks, the per-
centage increased to 53%. Meanwhile, the fraction of 
carriers of the virus with the N155H mutation shrank 
from 45 to 18% [60]. The probability of emergence of 
raltegravir-insusceptibility decreased in patients with 
reduced viral load (< 100,000 copies/ml) and in patients 
who were administered other active antiretroviral 
drugs.REVIEWS
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A similar pattern was revealed in trial P005 [54]. In 
20 and 14 patients out of 35 who appeared to be un-
susceptible to raltegravir, the virus contained mainly 
the Q148K/R/H or N144H mutation, respectively. Mu-
tations N155H and Q148K/R/H reduced the sensitiv-
ity of HIV patients to the action of raltegravir by fac-
tors of 10 and 25, respectively. Similar to that in trial 
BENCHMRK-1 and -2, mutation Q148K/R/H turned 
out to be associated with the secondary substitutions 
E138K and G140S/A. The secondary mutations L74M, 
E92Q, and G163R were revealed, and no substitutions 
T97A and V151I were found in the case of N155Н. The 
probability of resistance development decreased upon   
reduced viral load and when using additional HAART 
active components [54].
The recently obtained data in study [62] in which the 
effect of raltegravir on the strand carrier reaction per-
formed by wild-type IN or IN containing a mutation 
G140S, Q148H, or a double mutation G140S/Q148H 
are also of interest. It was evident that while the 
G140S mutation results in the emergence of small 
resistance (IC50(WT) = 10 nM, IC50(G140S) = 30 nM), 
IN with the Q148H or G140S/Q148H mutations has a 
very high raltegravir resistance (IC50(Q148H) > 70 nM, 
IC50(G140S/Q148H) > 1000 nM). In addition, it was as-
certained that the G140S mutation in the IN gene re-
covers the weak infectivity of the virus with the Q148H 
mutation to the level of the wild-type virus [62].
RALTEGRAVIR ANALOGUES – INHIBITORS 
OF HIV-1 INTEGRATION 
The emergence of a new drug, as in the case of any 
other kind of innovation, results in the rapid appear-
ance of a number of its analogues. Taking into account 
the approximate cost of the development, trials, and 
implementation of a single drug, which is equal to $ 
2 million, together with the fact that only one out of 
three novel therapeutic agents manage to recoup this 
expenditure [18], it is clear that the temptation exists 
for pharmaceutical companies to avoid the difficulties 
associated with the development of a completely new 
drug and confine themselves to modifying the drug 
that is the best for the moment. Therefore, raltegra-
vir, being the only licensed inhibitor of HIV integrase 
so far, is of immense interest as a starting point in the 
development of integration inhibitors. Raltegravir 
analogues are usually compounds based on diketo ac-
ids, which specifically suppress the IN strand transfer 
reaction due to chelating of Mg2+ ions in the enzyme 
active center [18]. In this section, we shall turn our at-
tention to the inhibitors of strand transfer eligible for 
the phase of clinical trials.
MK-2048
Soon after the permission for the use of raltegravir as 
a therapeutic agent was obtained, Merck Pharmaceu-
ticals  attempted to design pharmacophore, typical of 
diketo acids and capable of interacting with the metal 
ion on the basis of tricyclic dihydroxypyrrole deriva-
tives [63]. As a result, the MK-2048 inhibitor was de-
signed (Fig. 5), which exhibited a high inhibition ac-
tivity in all experiments (Table 5). The inhibitor has a 
good pharmacokinetic profile and, more importantly, 
possesses potential activity with respect to four mutant 
IN forms that are resistant to raltegravir. МК-2048 is 
currently undergoing clinical trials [18].
MK-2048  BMS-707035  GSK-364735  GS-9137
(5)    (6)    (7)    (8)    (9)
Fig. 5. Structures of HIV-1 integrase strand transfer inhibitors: MK-2048, BMS-707035, GSK-364735, GS-9137, and 
some new inhibitor classes: dihydroxypyrimidines (5), N-methyl pyrimidinone carboxamides (6), dihydroxypyrido-pyra-
zine-1,6-diones (7), bicyclic pyrimidones (8), pyrrolloquinolones (9).22 | ACTA NATURAE |  VOL. 3  № 3 (10)  2011
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BMS-707035
The structural and functional motifs of inhibitors 
L-780.810 and raltegravir are combined in the struc-
ture of this inhibitor [16]. BMS-707035 differs from 
raltegravir only by the substitution of the oxadiazole 
group for the cyclic sulfonamide group (Fig. 5) and 
possesses in vitro inhibiting activity that is similar to 
that of raltegravir (Table 5). BMS-707035 has reached 
the second phase of clinical trials; however, multiple 
mutations emerged in the IN gene responding to the 
therapy, which has led to the emergence of resistant 
HIV strains [16]. In the beginning of 2008, the clinical 
trials of BMS-707035 were discontinued.
GSK-364735
The GSK-364735 inhibitor (Fig. 5), a naphthyridinon 
derivative [68], was developed by the merged Shiono-
gi-GlaxoSmithKline Pharmaceuticals company on the 
basis of one of the first inhibitors of strand transfer 
S-1360 [42]. It was efficient in the suppression of HIV 
replication in MT-4 cells (Table 5) and possessed a low 
cytotoxicity (СС50 > 10 µM). The investigation of the 
action of GSK-364735 on HIV strains containing muta-
tions in the IN gene has demonstrated that the inhibi-
tor is more active to a certain extent with respect to the 
viruses with mutations T66I (by a factor of 1.2), E92Q 
(by a factor of 3.7), P145S (by a factor of 1.4), Q146R 
(by a factor of 1.7), and Q153Y (by a factor of 1.4) as 
compared with its activity towards the wild-type virus. 
However, a considerable reduction in the activity of the 
GSK-364735 inhibitor was observed in the case of four 
main mutations in the gene of HIV-1 integrase, which 
result in resistance development: by factors of 17 (T66K 
mutation), 210 (Q148K mutation), 73 (Q148R mutation), 
and 23 (N155H mutation) [68]. It was ascertained at the 
preclinical research phase that GSK-364735 has an ac-
ceptable pharmacokinetic profile; the bioavailability 
indices F (42, 12, and 32%), the half-excretion period 
from blood plasma T1/2 (1.5, 1.6, and 3.9 h), and plasma 
clearance Clp (3.2, 8.6, and 2 ml/min/kg) were obtained 
on rats, dogs, and rhesus macaques, respectively [68]. 
The drug had good indices at the first phase of clinical 
trials: it was ascertained that GSK-364735 is capable 
of reducing the viral load by a factor more than 100. 
However, the clinical trials ceased at the second phase 
due to hepatotoxicity being revealed [68, 69].
S/GSK1349572
Shionogi-GlaxoSmithKline Pharmaceuticals  has re-
ported that they have designed a highly efficient in-
hibitor S/GSK1349572 (Table 5) [70]. The authors have 
not disclosed the structure of this compound, but they 
claim that the agent is capable of  specific inhibition of 
the strand transfer reaction; the mechanism of its ac-
tion being based on chelating of Mg2+ ions in the active 
centre of the IN [70]. These facts allow us to tentatively 
attribute S/GSK1349572 to raltegravir analogues, if 
not in terms of structural characteristics, then at least 
on the basis of its effect on IN. The use of this prepara-
tion results in the development of mutations in the IN 
gene; however, they are incapable of providing a high 
degree of virus resistance to S/GSK1349572. Interest-
Table 5.  Results of in vitro and cell studies of raltegravir analogues as HIV-1 integration inhibitors
Compound IC50 , in vitro
(strand transfer), nM
CIC95
ex vivo Reference
MK-2048 10 35 nM (50% NHS) [63]
BMS-707035 20 - [16]
GSK-364735 8 EC50 = 1.2 nM
EC90 = 42 nM (20% NHS) [68]
S/GSK 1349572 2.7 EC50 = 0.5 nM
EC90 = 2 nM [13]
GS-9137 (elvitegravir) 7 EC50 = 0.7 nM
EC90 = 1.7 nM (20% NHS) [72]
(5) (dihydroxypyrimidine) 10 > 10 µM (10% FBS) [48]
(6) (N-methylpyrimidinone) 20 10 nM (10% FBS)
20 nM (50% NHS) [64]
(7) (dihydroxypyrido-pyrasine-1,6-dion) 100 310 nm (10% FBS)
310 nM (50% NHS) [65]
(8) bicyclic pyrimidinone 7 16 nM (10% FBS)
31 nM (50% NHS) [66]
(9) pyrrolquinolone 13 7 nM (10% FBS)
16 nM (50% NHS) [67]REVIEWS
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ingly, the inhibitor turned out to be active with respect 
to the HIV strains that were resistant to raltegravir [70] 
and elvitegravir (see below). This drug is likely to have 
a different resistance profile [14]. Nevertheless, certain 
secondary mutations that are additional to G140S/
Q148H, such as T97A, M154I or V201, induce resistance 
both to S/GSK1349572 and raltegravir [71]. These data 
point to the necessity of subjecting the emergence of 
HIV-1 resistance to this inhibitor to further study.
It was established by studying healthy volunteers 
that S/GSK1349572 has a rather positive pharmacoki-
netic profile; in particular, its bioavailability upon pero-
ral administration was approximately 70%, its period 
of half-excretion from blood plasma Т1/2 being higher 
than 15 h [70]. At the time of writing, the second phase 
of clinical trials of S/GSK1349572 is in progress [70].
GS-9137 (elvitegravir)
The attempts to modify DKS pharmacophore made by 
Japan Tobacco (Japan) resulted in the design of a group 
of IN inhibitors based on 4-oxoquinoline, which re-
tained the arrangement of the major functional groups 
that are required for the interaction with metal ions 
[72]. The cooperation agreement between Japan Tobac-
co and Gilead Sciences (United States) signed in 2005, 
laid the foundation for the clinical trials of the GS-9137 
inhibitor (Fig. 5) [16] named elvitegravir, as well as the 
most active representative of IN inhibitors belonging 
to this structural class (Table 5). The pharmacokinetic 
profile of elvitegravir was studied on rats and dogs [73]. 
The drug had good indices of bioavailability F (34 and 
30%), period of half-excretion from blood plasma Т1/2 
(2.3 and 5.2 h) and plasma clearance Clp (8.3 and 17 ml/
min/kg) in rats and dogs, respectively [73].
The pharmacokinetic profile of elvitegravir was 
studied in both healthy [74] and HIV-infected [75] vol-
unteers. It was established that elvitegravir rapidly 
assimilates (3.5–4 h); an increase in Сmax and AUC pa-
rameters was observed with an increasing elvitegravir 
dose. The best results were obtained when administer-
ing elvitegravir together with ritonavir (protease inhib-
itor) [75]. Unlike raltegravir, elvitegravir is metabolized 
by cytochrome P450 (CYP3A4) [74]. The stimulating 
action of ritonavir is probably the result of its ability 
to inhibit Р450 cytochrome and thus maintain a higher 
concentration of elvitegravir. The interaction between 
elvitegravir and nucleoside and non-nucleoside inhibi-
tors of reverse transcriptase and penetration inhibitor 
maraviroc was also studied. It turned out that these in-
hibitors have no considerable effect on the efficacy of 
elvitegravir [74].
A randomized study of the therapeutic activity of 
elvitegravir was performed on 278 HIV-infected pa-
tients who had earlier received HAART and developed 
resistance to its components [76]. The patients with a 
viral load of approximately 30,000 copies/ml and CD4 
lymphocyte count of approximately 200 cells/µl were 
given the combination of elvitegravir and ritonavir 
once per day. After week 24 of  trial, the viral load de-
creased by a factor of at least 10 in 90% of the patients 
who had been administered elvitegravir. The viral load 
decreased by a factor of 100 in 76% of the individuals 
who were given 125 mg of elvitegravir and 69% of those 
who were administered 50 mg of elvitegravir [76]. The 
study was also performed on 40 HIV-infected volun-
teers with a viral load of 10,000–300,000 copies/ml and 
an average CD4 cell count of approximately 200 cells/
µl, who received elvitegravir at different doses once or 
twice a day or once a day in combination with ritona-
vir. The viral load decreased on average by a factor of 
80 in the groups administered elvitegravir twice a day 
and those administered the combination of elvitegravir 
and ritonavir, after 10 days. However, no statistically 
significant change in the CD4 cell count has been ob-
served [75].
A randomized double-blind study of the effect of 
elvitegravir on HIV-infected volunteers who were 
naïve to HAART was carried out for 48 weeks [77]. The 
patients tested were divided into two groups: one of 
those received a mixture of elvitegravir with cobicistat, 
the inhibitor of cytochrome Р450; the second group was 
given the non-nucleoside inhibitor of reverse tran-
scriptase efavirenz. In addition, both groups were ad-
ministered two nucleoside inhibitors of reverse tran-
scriptase, emtricitabine /tenofovir. It appeared that the 
fraction of patients with an undeterminable viral load 
in both groups reached 83% and 90% after weeks 24 and 
48, respectively [77]. Thus, elvitegravir manifested a 
high efficacy, which was comparable with the efficacy 
of the commonly used antiviral agent efavirenz.
The data on the safety of elvitegravir is limited by 
the results of the second phase of trials, in which HIV-
infected patients were given an elvitegravir/ritonavir 
mixture or a competitive protease inhibitor [76]. No no-
ticeable differences between the two groups in terms of 
either the frequency of side-effects, or their severity, 
was observed. Additional studies are required to con-
firm how  safe  elvitegravir is in the treatment of HIV-
infected patients. At the time of writing, elvitegravir is 
undergoing the third phase of clinical trials.
Analysis of  resistance development in the individu-
als administered elvitegravir is confined to the data 
obtained using HIV isolates collected from the pa -
tients participating in the second phase of clinical trials 
[52, 78]. Primary mutations E92Q, T66I/A/K, E138K, 
S147G, Q148R/H/K, and N155H in HIV-1 integrase 
were the most frequent; they are also associated with   
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raltegravir [79]. At least one of the primary mutations 
was detected in 39% of elvitegravir-resistant individu-
als. In addition, cross-resistance to raltegravir was de-
tected: on average, a decrease in the susceptibility to 
elvitegravir by a factor of 150 also resulted in a 30-fold 
reduction of susceptibility to raltegravir. The cross-re-
sistance of HIV to the action of raltegravir and elvite-
gravir was verified by the results of cell studies [80]. 
Elvitegravir-resistant HIV strains were isolated, and   
increased resistance to raltegravir and the derivatives 
of diketo acid L-731.988 and naphthyridine L-870.810 
was detected [80].
New raltegravir-based inhibitors 
of HIV-1 integration
The conduct of a large number of studies aimed at 
searching for new raltegravir-based IN inhibitors re-
sulted in the development of IN inhibitors belonging 
to several novel structural classes. They all  specifically 
inhibit the strand transfer reaction and contain func-
tional groups that are capable of chelating metal ions in 
the IN active centre [18]. The names of the new struc-
tural classes of IN inhibitors, the structure of individual 
representatives (Fig. 5) with the indication of their ac-
tivity in vitro and in cell studies, and the data on study-
ing pharmacokinetics in rats are presented in Table 5.
The problems of usage of raltegravir 
analogues as integration inhibitors
All the recorded data  point to the fact that the known 
raltegravir analogues act upon HIV-1 integrase via the 
same mechanism, contain a similar structural motif, 
and manifest comparable activity in vitro and in cell 
studies. This type of identity casts some suspicion on 
the successful future application of these inhibitors 
as therapeutic agents. These suspicions are caused by 
cross-resistance of the virus to these inhibitors.
First of all, the emergence of cross-resistance can be 
accounted for by the similar mechanism of binding of 
strand transfer inhibitors to the IN complex and viral 
DNA [14]. As a result of the manner of binding of these 
compounds, they “push” the 3’-terminal hydroxyl of the 
processed DNA strand out of the enzyme active centre, 
thus blocking the integration. This binding mechanism 
was proposed for HIV-1 IN [81] and demonstrated for 
the enzyme of the human foamy virus (Fig. 6) [28]. Study 
[28]  was first to show that the position of 3’-hydroxyl is 
occupied by the fluorobenzyl residue of the inhibitor, the 
fundamentally necessary structural element of all strand 
transfer inhibitors (Figs. 4 and 5).
Using  data on X-ray diffraction of the catalytic do-
main of IN in its complex with Mg2+ (1BL3) [18], molec-
ular docking of certain IN inhibitors based on DKC was 
performed. According to the model proposed, raltegra-
vir interacts with the T66, E92, Y143, Q148, and N155 
residues, their substitution resulting in a decrease in 
the susceptibility to raltegravir by a factor varying 
from 5 to 35 [48, 82]. Molecular docking also confirmed 
the fact that amino acid residues interacting with GSK-
364735 and GS-9137 are identical to those interacting 
with raltegravir [83, 84], with an exception for G140. 
For the latter, a similarity is observed only in the case 
of elvitegravir [18]. This result correlates with the data 
demonstrating that the G140S mutation reduces HIV-1 
susceptibility to elvitegravir by a factor of 4; and that 
to raltegravir, only by a factor of 1.6.
Molecular docking of certain new IN inhibitors 
(Fig. 5) demonstrated that these compounds bind to IN 
in a manner similar to that of raltegravir. Hence, if the 
results of the study [18] are valid, it is rather unlikely 
that new inhibitors based on raltegravir will turn out 
to be active with respect to HIV strains that are ralte-
gravir-resistant and, therefore, become an adequate 
substitution for it.
Another problem that could complicate the suc-
cessful use of integration inhibitors is the scarcity of   
knowledge on IN polymorphism in various subtypes 
of HIV-1. Until recently, only one study had been 
performed in which the susceptibility of 137 clinical 
isolates to raltegravir had been tested. Sixty of those 
isolates did not belong to the B-subtype [85]. No differ-
ences were revealed. However, it was demonstrated in 
А     B     C Fig. 6. Structure 
of the active site 
of human foamy 
virus integrase 
in the absence 
of inhibitor (A), 
in the presence 
of MK-0518 (B), 
and GS-9137 (C) 
[28].REVIEWS
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in vitro experiments that the IN of the C-subtype virus 
containing the E92Q/N155H mutation is more suscep-
tible to raltegravir and elvitegravir by a factor of 10 as 
compared with the enzyme of B-subtype HIV-1 [86]. It 
has also been demonstrated that the mutations of the 
G140 residue occur less frequently in the CRF02 AG-
subtype virus as compared with those in the B-subtype 
virus [87]. Data are available that raltegravir appears to 
be inefficient more frequently on  individuals infected 
with a non-B-subtype virus [88].
ALTERNATIVE PATHS OF INHIBITION 
OF HIV-1 INTEGRATION
We believe that the optimal alternative way of search-
ing for inhibitors of HIV-1 integration consists in de-
signing inhibitors with a mechanism of action that dif- a mechanism of action that dif-  mechanism of action that dif-
fers from that of raltegravir and its analogues, which 
specifically inhibit the strand transfer.  We shall pro-
vide only a brief characterization of several classes of 
IN inhibitors that differ from the inhibitors of strand 
transfer in terms of their mechanism of action, and 
specify certain representatives of these inhibitors.
Inhibitors of 3’ processing
The inhibitors belonging to this class are likely to sup-
press both integration stages: both 3’ processing and 
the strand transfer. It occurs due to the fact that they 
interact with the active centre of the enzyme, rather 
than with the enzyme–DNA substrate complex. It is 
an appreciably numerous class of inhibitors; styryl qui-
noline compounds being the best-studied inhibitors 
of 3’ processing [89]. Styryl quinoline KHD161 (Fig. 7) 
has nearly the same effect both on 3’ processing (IC50 = 
2.4 µM) and the strand transfer (IC50 = 1 µM). It is ca-
pable of suppressing the cytopathic effect of HIV-1 in 
cells with CIC50 = 1.3 µM [90, 91]. IN inhibitors based on 
styryl quinoline are known to be incapable of destroy-
ing the pre-formed IN–DNA substrate complex and 
inhibiting the reaction of 3’ processing with its partici-
pation. Moreover, the ability of styryl quinolines to bind 
onto IN depends on Mg2+ ions [92]. Thus, a competitive 
mechanism of IN inhibition with styryl quinolines, due 
to the interaction with a metal ion in its active centre, 
can be proposed.
Allosteric inhibitors 
Inhibitor V-165 (Fig. 7), belonging to the class of 5H-
pyrano[2,3-d:-6,5-d’]dipyrimidines, prevents IN bind-
ing with the DNA substrate. It is more efficient in in-
hibiting the reaction of 3’ processing (IC50 = 0.9 µM), in 
comparison with that of the strand transfer (IC50 = 16 
µM) [93]. Moreover, V-165 suppresses HIV infection in 
a cell culture [93]. A double mutation T206S/S230N in 
the IN gene was successfully identified by the selection 
of virus strains resistant to the inhibitor V-165, since 
the mutation is located in the C-terminal domain of IN, 
its main function consisting in DNA binding [94].
Inhibitors of integrase multimerization
The search for compounds with an effect on the inter-
action between the IN and components of the HIV-1 
preintegration complex or on their own ability to form 
an active multimer is currently  actively under way 
[95]. Hydroxycoumarin derivatives refer to the com-
pounds that suppress IN multimerization. It has been 
demonstrated that hydroxycoumarin tetramer (Fig. 7) 
suppresses HIV-1 replication in a cell culture with 
the value СIC50 = 11.5 µM) [96]. It can inhibit the ac-
tivity of HIV-1 integrase in vitro. Hydroxycoumarin 
tetramer inhibits 3’ processing and strand transfer 
(IC50 = 1.5–2.0 µM) [96]. The benzophenone derivative 
of hydroxycoumarin was crosslinked to integrase in 
order to identify the site of inhibitor–enzyme binding 
[97]. Peptide 128AACWWAGIK136, to which the inhibitor   
binds, has been determined [97]. This peptide partici-
pates in the dimeric complex formation of the catalytic 
domain [39]. Thus, the hydroxycoumarin-based inhibi-
tor is bound to the enzyme near the surface of contact 
between two monomers. The binding of hydroxycou-
marin derivatives with IN near the 128AACWWAGIK136 
peptide can disturb  interaction of this kind and can 
have an effect on the formation and stability of the 
catalytically active integrase multimer. 
Inhibitors of the interaction between 
integrase and LEDGF/p75
This is the least explored direction in the search for 
integration inhibitors. Regardless of the fact that PIC 
KHD161  
V-165
Hydroxycoumarin 
tetramer
CHIBA-3003
Fig. 7. Structures of KHD161, V-165, hydroxycoumarin 
tetramer, and CHIBA-3003.26 | ACTA NATURAE |  VOL. 3  № 3 (10)  2011
REVIEWS
contains a large number of viral and cellular proteins 
in addition to IN, it is its interaction between IN and its 
cellular partner LEDGF/p75 that determines HIV-1 
integration [95].  Data on the inhibitors capable of de-
stroying the IN/LEDGF complex is rather scarce; what 
we know so far is that their activity is likely to be low. 
The CHIBA-3003 compound (Fig. 7) was designed using 
a computer simulation. It is capable of destroying the 
IN/LEDGF complex with IC50 = 35 µM [98]. The effect 
of the LEDGF 355IHAEIKNSLKIDNLDVRNCIEAL377 
peptide on the stability of the IN/LEDGF complex 
and catalytic activity of IN has been studied [99]. It ap-
pears that this peptide impedes the formation of the 
IN/LEDGF complex with IC50 = 25 µM and inhibits 3’ 
processing and strand transfer with IC50 = 160 µM [99].
CONCLUSIONS
In 1996, the resources allocated to research, treatment, 
and prevention of the spread of HIV/AIDS amounted 
to 300 million USD. Since then, they have been steadily 
increasing, to approximately 10 million USD a year at 
the time of writing [18]. A considerable portion of these 
funds is spent on the development of new inhibitors 
aimed at the suppression of viral enzymes, including IN. 
During the 2.5 years that have elapsed since raltegra-
vir was certified for use as a therapeutic agent against 
HIV-1, the major efforts of pharmaceutical companies 
such as Merck Pharmaceuticals, Japan Tobacco, Gilead 
Sciences, and Shionogi-GlaxoSmithKline Pharmaceu-
ticals have focused on developing  analogues of this 
drug. Yet, many raltegravir analogues are incapable 
of suppressing the replication of HIV-1 strains that are 
raltegravir-resistant [83, 84]. We consider that there 
is a need for a more active search for inhibitors with 
a different mechanism of action, which can be active 
with respect to the raltegravir-resistant viral strains. 
However, it should be mentioned that none of the in-
hibitors of HIV-1 integration that do not belong to the 
class of specific inhibitors of strand transfer has so far 
managed to successfully pass even the first phase of 
clinical trials. 
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